公开(公告)号：EP1609860B1

公开(公告)日：2010-03-17

申请号：EP04723360.6

申请日：2004-03-25

申请人： Juridical Foundation The Chemo-Sero-Therapeutic Research Institute ,  Kowa Co., Ltd.

发明人： NAKASHIMA, Toshihiro, c/o Juridical Foundation ,  SASAKI, Takumi, c/o Juridical Foundation ,  KIMACHI, Kazuhiko, c/o Juridical Foundation ,  KUWATA, Shigeki, c/o Juridical Foundation ,  NISHIHARA, Tsukasa, c/o Juridical Foundation ,  SAKATA, Atsuko ,  OHKUCHI, Masao ,  KOSHI, Tomoyuki ,  EDANO, Toshiyuki

IPC分类号： C12N15/09 ,  C07K14/47 ,  A61K38/17 ,  A61P37/08

CPC分类号： A61K38/164 ,  C07K14/31 ,  C07K16/1271

公开(公告)号：EP2006305A9

公开(公告)日：2009-07-15

申请号：EP07737666.3

申请日：2007-03-02

申请人： Tokyo University of Science ,  Juridical Foundation The Chemo-Sero-Therapeutic Research Institute ,  Teijin Pharma Limited

发明人： MASUHO, Yasuhiko, c/o Tokyo University of Science ,  NAGASHIMA, Hiroaki, c/o Tokyo University of Science

IPC分类号： C07K16/46 ,  C07K16/28 ,  C12N15/09 ,  C12P21/08

CPC分类号： C07K16/2887 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2319/30

摘要： The present inventors generated modified antibodies in which several Fc domains are linked in tandem to the C terminus of the heavy chain, and modified antibodies in which Fc domains are linked in tandem via spacers, and measured the affinity for Fc receptors, CDC activity, and ADCC activity. A previous report indicated that CDC activity is not enhanced by linking multiple Fcs. However, the modified antibodies of the present invention exhibited enhanced ADCC activity. The methods of the present invention enable provision of antibody pharmaceuticals having a marked therapeutic effect.

公开(公告)号：EP1705720A3

公开(公告)日：2009-03-25

申请号：EP06006034.0

申请日：2006-03-23

申请人： International Superconductivity Technology Center, The Juridical Foundation ,  SWCC SHOWA CABLE SYSTEMS CO., LTD. ,  FUJIKURA LTD.

发明人： Aoki, Yuji c/o Superconductor Project SWCC Showa ,  Fuji, Hiroshi c/o Metallic Material Dept. ,  Nomoto, Sukeharu c/o Energy &Industrial Sys. Dept. ,  Teranishi, Ryo c/o Dept. of Materials Science & ,  Izumi, Teruo c/o Superconductivity Research Lab. ,  Shiohara, Yuh c/o Superconductivity Research Lab.

IPC分类号： H01L39/24 ,  F27B9/04

CPC分类号： F27B9/04 ,  H01L39/2451 ,  Y10S505/73 ,  Y10S505/74 ,  Y10S505/741 ,  Y10T29/49014

摘要： A method of manufacturing a tape-formed oxide superconductor, in which a tape-formed wire material (6) is extended between a pair of reels (5a and 5b) . Besides, a reactive gas is supplied from the gas supply ports of a reactive gas supply pipe (3a) vertically to the upper side film surface of the tape-formed wire material (6), so as to react the film body of this tape-formed wire material into a superconducting layer, while at the same time, a gas after the reaction is discharged from the gas discharge ports of discharge pipes (4a and 4b) for discharging the gas after the reaction. Likewise, the reactive gas is supplied via gas supply pipe (3b) vertically to the lower side film surface of the tape-formed wire material (6), so as to react the film body of this tape-formed wire material into a superconducting layer, while at the same time, the gas after the reaction is discharged from the gas discharge ports of discharge pipes (4c and 4d) for discharging the gas after the reaction. Even when the tape-formed wire material (6) is large in area, the tape-formed oxide superconductor has superconducting characteristics being uniform in its widthwise direction, and it can be manufactured at high speed.

公开(公告)号：EP1978355A1

公开(公告)日：2008-10-08

申请号：EP07707104.1

申请日：2007-01-19

申请人： Juridical Foundation Osaka Industrial Promotion Organization ,  Osaka University

发明人： KUWABATA, Susumu ,  TORIMOTO, Tsukasa

IPC分类号： G01N23/225 ,  G01N1/28 ,  G01N23/04 ,  H01J37/20

CPC分类号： G01N23/225 ,  G01N1/30 ,  H01J37/20 ,  H01J2237/0044 ,  H01J2237/2004

摘要： An object of the present invention is to provide a medium; a specimen; a method for preparing the specimen; a method for observing the specimen; a sample cell; and an electron microscope capable of easily solving the problem of charge-up and further capable of observing a real shape or the like of a sample with a SEM, a TEM or the like. For the purpose of achieving the above-described object, the present invention uses an electrical conductivity-imparting liquid medium, for use in a microscope, which includes an ionic liquid as an essential component thereof and is impregnated into the entirety of a SEM or TEM sample or applied to the observation surface of a SEM or TEM sample to impart electrical conductivity at least to the observation surface of the sample. According to the present invention, the charge built up on the sample surface can be released simply by impregnating or coating the sample with the ionic liquid, and hence the problem of charge-up can be easily solved. Further, even when a sample impregnated or coated with the ionic liquid is placed under vacuum, the ionic liquid is not evaporated from the sample, and hence a biological sample can be observed as it is in an original shape.

摘要翻译： 本发明的一个目的是提供一种介质; 样本; 用于制备样品的方法; 用于观察标本的方法; 样品池; 和上能够解决轻松的过度充电的麻烦并且还能够观察真实形状等用SEM，TEM一个或类似物的样品的电子显微镜。 为了实现上述目的的目的，本发明使用的导电性赋予液体培养基中，用在显微镜，在离子液体包括作为其必要成分，并浸渍到SEM或TEM的整体性 样品或施加到SEM或TEM样品的表面观察到赋予导电性至少与样品的观察面。 。根据本发明，建立了样品表面上的电荷，可以简单地通过浸渍或涂覆与离子液体样品释放，并​​因此充了麻烦可以容易地解决。 此外，即使当浸渍或与离子液体涂布的样品放置在真空下，离子液体不从样品蒸发，因此生物样品可以观察到，因为它是在到原来的形状。

公开(公告)号：EP1688785A4

公开(公告)日：2008-02-13

申请号：EP04818553

申请日：2004-11-16

申请人： JURIDICAL FOUNDATION OSAKA IND

发明人： KITAYAMA KEN-ICHI ,  IKEDA KENSUKE ,  JALIL MOHAMMAD ABDUL ,  NAMIKI SHU ,  INOUE TAKASHI

IPC分类号： G02F7/00 ,  G02F1/365 ,  G02F2/02 ,  G02F3/00

CPC分类号： H04B10/299 ,  G02F1/3519 ,  G02F3/00 ,  G02F7/00 ,  G02F2002/006

摘要： An optically encoding circuit (200) uses a plurality of optical encoders including an optical non-linear element having a periodicity different in I/O characteristics associated with light intensity, so as to optically encode a signal light pulse string having a first wavelength according to control light as a pulse string of an optical analog signal having a second wavelength in the vicinity different from the first wavelength and optically sampled, and output the optically-encoded signal light pulse strings from the optical encoders. A light quantization circuit (300) uses a plurality of light threshold value processors connected to the respective optical encoders and including an optical non-linear element having I/O characteristic associated with light intensity having periodicity, so as to subject the carrier light pulse string having the third wavelength in the vicinity different from the first wavelength to the light threshold value processing and light quantization according to the signal pulse light strings which have been optically encoded, and output it as an optical digital signal.

公开(公告)号：EP1640999A1

公开(公告)日：2006-03-29

申请号：EP04724718.4

申请日：2004-03-31

申请人： International Superconductivity Technology Center, The Juridical Foundation ,  Sumitomo Electric Industries, Ltd. ,  Ishikawajima-Harima Heavy Industries Co., Ltd.

发明人： MAEDA, Toshihiko ,  IZUMI, Toru ,  HASEGAWA, Katsuya ,  ASADA, Shigenobu ,  IZUMI, Teruo ,  SHIOHARA, Yuh

IPC分类号： H01B12/06

CPC分类号： H01L39/2454 ,  Y10T29/49014

摘要： A metal substrate for an oxide superconducting wire, which comprises a polycrystalline metal substrate with a rolled aggregate structure having a {100} plane which is parallel to the rolled surface and a axis which is parallel to the rolling direction, and an oxide crystal layer comprising an oxide of the polycrystalline metal and formed on a surface of the polycrystalline metal substrate, wherein at least 90% of grain boundaries in the oxide crystal layer have an inclination of 10° or less, and at least 90% of the {100} plane of the oxide crystal layer make an angle of 10° or less with the surface of the polycrystalline metal substrate.

摘要翻译： 用于在氧化物超导线材，其包括与具有{100}面的所有平行于轧制面和轧制集合组织的多晶金属基材的金属基材一个<001>轴的所有的平行于轧制方向，以及氧化 晶体层的多晶金属的氧化物的含有和形成的多晶金属基材的表面上，氧化物晶体层在晶界的worin至少90％具有在10度以下的倾斜，以及至少90％的{ 100}的氧化物结晶层的面内使10°或更小的角度与所述的多晶金属基材的表面上。

公开(公告)号：EP1621615A1

公开(公告)日：2006-02-01

申请号：EP04727416.2

申请日：2004-04-14

申请人： Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute

发明人： KOYANAGI, Satoshi, Chemo-Sero Therap. Res. Kikuchi ,  KAWATSU, Kenjiro, Chemo-Sero Therap. Res. Kikuchi ,  MURAKAMI, Toshio, Chemo-Sero Therap. Res. Kikuchi ,  MIYATSU, Yoshinobu, Chemo-Sero Therap. Res Kikuchi ,  MAEDA, Toshihiro, Chemo-Sero Therap. Res. Kikuchi ,  MIZOKAMI, Hiroshi, Chemo-Sero Therap. Res. Kikuchi

IPC分类号： C12N15/09 ,  C07K14/435 ,  A61K38/17 ,  A61P37/08

CPC分类号： C07K14/43531 ,  A61K38/00 ,  A61K39/00

摘要： A method for purifying a modified major mite allergen obtained by the genetic recombination technique and a purified modified major mite allergen obtained by said method for purification are provided. A method for purifying a modified major mite allergen obtained by the genetic recombination technique, which comprises the purification steps: (1) Washing and recovering inclusion bodies containing a modified major mite allergen obtained by the genetic recombination technique with MF membrane; (2) Dissolving said inclusion bodies followed by refolding; (3) Concentrating a solution containing the modified major mite allergen with simultaneous removal of low molecular weight components with ultrafiltration membrane; (4) Recovering the modified major mite allergen in non-adsorbed fractions with an anion exchanger; (5) Recovering the modified major mite allergen in adsorbed fractions with a hydrophobic gel; and (6) Recovering the modified major mite allergen in adsorbed fractions with an anion exchanger, and a modified major mite allergen with high purity obtained by said method for purification.

摘要翻译： 提供了通过遗传重组技术获得的改良的主要螨变应原的纯化方法和通过所述纯化方法获得的纯化的改性主要螨变应原。 一种用于纯化通过遗传重组技术获得的改性主要螨变应原的方法，其包括纯化步骤：（1）洗涤并回收含有通过MF膜的遗传重组技术获得的修饰的主要螨变应原的包含体; （2）溶解所述包涵体，然后重折叠; （3）浓缩含有改性主要螨变应原的溶液，同时用超滤膜除去低分子量组分; （4）用阴离子交换剂回收未吸附级分的改性主要螨变应原; （5）用疏水凝胶回收吸附级分中的改性主要螨变应原; 和（6）用阴离子交换剂回收吸附级分中的改性主要螨变应原，以及通过所述纯化方法获得的具有高纯度的改性主要螨变应原。

公开(公告)号：EP1617477A1

公开(公告)日：2006-01-18

申请号：EP04719623.3

申请日：2004-03-11

申请人： Juridical Foundation Osaka Industrial Promotion Organization

发明人： AKINO, Toshiro, c/o Kinki University

IPC分类号： H01L27/092 ,  H01L27/06 ,  H01L29/786

CPC分类号： H01L27/0705 ,  H01L27/092 ,  H01L27/1203 ,  H01L29/1087 ,  H03K2217/0018

摘要： A lateral bipolar CMOS integrated circuit having an inverter circuit including an n-channel MOS transistor and a p-channel MOS transistor, and having four terminals of: a gate input terminal Vin connected with the gates of the n-channel MOS transistor and the p-channel MOS transistor; an output terminal Vout connected with the drains of the n-channel MOS transistor and the p-channel MOS transistor; a p-type base terminal connected with a p-type substrate of the n-channel MOS transistor; and an n-type base terminal connected with an n-type substrate of the p-channel MOS transistor. The n-channel MOS transistor operates in a hybrid mode which is the hybrid of an operation mode of the MOS transistor and that of an npn lateral bipolar transistor which is inherent in the n-channel MOS transistor. The p-channel MOS transistor operates in a hybrid mode which is the hybrid of an operation mode of the MOS transistor and that of a pnp lateral bipolar transistor which is inherent in the p-channel MOS transistor.

摘要翻译： 一种横向双极CMOS集成电路，具有包括n沟道MOS晶体管和p沟道MOS晶体管的逆变器电路，并且具有四个端子：与n沟道MOS晶体管的栅极连接的栅极输入端子Vin和p 通道MOS晶体管; 与n沟道MOS晶体管和p沟道MOS晶体管的漏极连接的输出端子Vout; 与n沟道MOS晶体管的p型衬底连接的p型基极; 以及与p沟道MOS晶体管的n型衬底连接的n型基极。 n沟道MOS晶体管以混合模式工作，该混合模式是MOS晶体管的工作模式与n沟道MOS晶体管固有的npn横向双极晶体管的工作模式的混合。 p沟道MOS晶体管以混合模式工作，该混合模式是MOS晶体管的工作模式和p沟道MOS晶体管固有的pnp横向双极晶体管的工作模式。

公开(公告)号：EP1614424A1

公开(公告)日：2006-01-11

申请号：EP04726619.2

申请日：2004-04-08

申请人： Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute

发明人： TAGAWA, R.; c/o J. F. Chemo-Sero-Theraupic R. I. ,  HAYASE, Y.; c/o J. F. Chemo-Sero-Theraupic R. I. ,  MAEMURA, K.; c/o J. F. Chemo-Sero-Theraupic R. I. ,  TANIGAWA, H.; c/o J. F. Chemo-Sero-Theraupic R. I.

IPC分类号： A61K38/38 ,  B01D61/14

CPC分类号： C07K14/76 ,  A61K38/38 ,  B01D61/147

摘要： An albumin preparation may be produced efficiently on a commercial basis that has reduced possibility of contamination of infectious viruses and has high safety and stability. The process according to the present invention comprises a step of filtration of a serum albumin-containing solution with a virus-removing membrane preferably with a pore size of 10 to 20 nm. In particular, said filtration is performed before heat treatment for inactivation of viruses. In a more preferable embodiment, said serum albumin-containing solution is treated with an anion exchanger and/or a prefilter before a step of said filtration.

摘要翻译： 可以商业上有效地生产白蛋白制剂，其具有降低感染性病毒污染的可能性并且具有高的安全性和稳定性。 根据本发明的方法包括用优选具有10至20nm的孔径的病毒除去膜过滤含血清白蛋白的溶液的步骤。 特别地，所述过滤在用于灭活病毒的热处理之前进行。 在更优选的实施方案中，所述含血清白蛋白的溶液在所述过滤步骤之前用阴离子交换剂和/或预过滤器处理。

公开(公告)号：EP1586328A1

公开(公告)日：2005-10-19

申请号：EP03768290.3

申请日：2003-12-26

申请人： Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute

发明人： OKAJIMA, Kenji ,  MATSUO, Fujio Jur.Found. The Chemo-Sero-Th. Res. ,  SUTOH, Hiroyuki Jur.Found. The Chemo-Sero-Th. Res. ,  OGATA, Yoichi JUR. FOUND. THE CHEMO-SERO-THERA. ,  NAKAGAKI, Tomohiro Jur.Found. The Chemo-Sero-Ther.

IPC分类号： A61K38/48 ,  A61P7/02 ,  A61P9/00 ,  A61P9/10 ,  A61P43/00

CPC分类号： A61K38/4866

摘要： A medicament for improving prognostic survival in therapy of malignant tumor is provided that may improve prognostic survival in DIC patients where the basal disease is malignant tumor, especially malignant tumor in hematopoietic organs. The medicament according to the invention comprises as a main active ingredient Activated Protein C, which is obtained from plasma or prepared by using the genetic recombination technique, and efficiently prolongs life-span of DIC patients where the basal disease is malignant tumor, especially malignant tumor in hematopoietic organs. In particular, the medicament may reduce adverse side effects of chemotherapeutics in chemotherapy of malignant tumor to enhance efficacy of said therapy and improve prognostic survival of patients suffering from malignant tumor.

摘要翻译： 提供了一种用于改善恶性肿瘤治疗预后生存的药物，可以改善基底疾病是恶性肿瘤，特别是造血器官恶性肿瘤的DIC患者的预后生存。 根据本发明的药物包含作为主要活性成分的活性蛋白C，其由血浆获得或通过使用遗传重组技术制备，并有效延长了基础疾病是恶性肿瘤，特别是恶性肿瘤的DIC患者的寿命 在造血器官。 特别地，药物可以减少化学治疗剂在恶性肿瘤化疗中的不良副作用，以增强所述治疗的疗效并改善恶性肿瘤患者的预后。